Published in final edited form as:

Angew Chem Int Ed Engl. 2012 May 21; 51(21): 5188–5191. doi:10.1002/anie.201200731.

Nonnatural Amino Acid Synthesis by Using Carbon-Hydrogen Bond Functionalization Methodology

Ly Dieu Tran and Prof. Dr. Olafs Daugulis

Department of Chemistry, University of Houston, Houston, TX 77204-5003, USA, Fax: (+1)713-743-2709

Olafs Daugulis: olafs@uh.edu

Keywords

palladium; C-H activation; amino acids; C-C coupling

During the last years, transition-metal-catalyzed carbon-hydrogen bond functionalization has witnessed an explosive growth.^[1] The use of C-H bond as a functional group is appealing because of shortening of reaction pathways and simplification of retrosynthetic analyses. However, most of the reports that deal with carbon-hydrogen bond conversion to carbon-carbon bonds involve either methodology development or mechanistic investigations. The applications in synthesis of natural products or their analogues are rare.^[2] The limited use may be explained by the following issues. First, methods that result in functionalization of alkane C-H bonds are relatively rare.^[3] Second, harsh reaction conditions are typically used that may be incompatible with sensitive functionalities. Third, methods often lack generality and require non-removable directing groups.

We have reported the β -arylation of carboxylic acid and γ -arylation of amine derivatives by employing an 8-aminoquinoline or picolinic acid auxiliary, catalytic Pd(OAc)₂, and an aryl iodide coupling partner (Scheme 1).^[4a] Subsequently, several other auxiliaries were investigated for carboxylic acid β -arylation.^[4b] Use of 2-thiomethylaniline auxiliary affords selective monoarylation of methyl groups. In contrast, use of 8-aminoquinoline auxiliary allows either diarylation of methyl or monoarylation of methylene groups. The arylation regioselectivity is determined by formation of double five-membered chelate **1**.

Several other groups have recently used these directing groups in synthesis of natural products.^[5] Corey has used the 8-aminoquinoline auxiliary to arylate sp³ C-H bonds in amino acid derivatives.^[5a] However, monoarylation of alanine derivatives was not demonstrated and stereochemical integrity of arylation products as well as directing group removal was not reported. Developing new methodology for unnatural amino acid synthesis is important since they are used in drug discovery, protein engineering, peptidomimetics, glycopeptide synthesis, and click chemistry in biologically relevant systems.^[6–7] Methods for preparation of chiral nonracemic unnatural α -amino acids involve synthesis of racemates followed by resolution, use of chiral auxiliaries, asymmetric hydrogenation, and biological approaches.^[8] A general method for unnatural amino acid synthesis from chiral pool would expand the toolbox that is available for their preparation. We report here a method of

Correspondence to: Olafs Daugulis, olafs@uh.edu.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.

palladium-catalyzed synthesis of protected unnatural amino acids by C-H bond functionalization that employs readily available starting materials derived from chiral pool.

The functionalization of amino acid C-H bonds requires installation of a directing group and protection of the amino group. Phthaloyl group was chosen for protection of the amino functionality.^[9] Directing group was installed by reacting phthaloylamino acid chlorides^[10] with 8-aminoquinoline or 2-thiomethylaniline. *N*-Phthaloylalanine derivative **2** was arylated by PhI in the presence of a palladium catalyst and base. Subsequently, directing group was removed by treatment with $\text{BF}_3 \cdot \text{Et}_2\text{O}$ in methanol at 100 °C (Table 1).^[11] Nearly identical enantiomeric excess of **4** was observed by employing AgOAc, AgOCOCF₃, or CsOAc bases at 60–70 °C (entries 3–8). Higher reaction temperatures resulted in erosion of product enantiomeric excess (entries 1, 4, 9), as did addition of pivalic acid (entry 2). The optimal combination of yield and enantiomeric excess was obtained by employing palladium acetate catalyst in combination with AgOAc at 60 °C (entry 5).

Use of 2-thiomethylaniline derivative allows for a selective monoarylation of methyl group in **2** (Scheme 2). Arylation of **2** by iodobenzene affords **3** in 78% yield. 4-Methoxyiodobenzene is reactive and the arylation product **5** was isolated in 68% yield. 2-Iodonaphthalene and 2-iodobenzothiophene afforded the products in good yields. β -(2-Naphthyl)alanine-containing peptides are highly specific Pin1 inhibitors.^[12] Interestingly, 3-iodo-1-methylindole can be coupled with **2** to give an *N*-methylated tryptophan derivative **8** in 61% yield. An azido functionality is tolerated and 3-azidophenylalanine derivative **9** was obtained in 81% yield. Thus, a wide variety of substituted phenylalanines can be made from a readily available, single starting material **2** in a convergent fashion. Two of the arylated derivatives were subjected to cleavage of directing group. *N*-Phthaloylphenylalanine methyl ester **4** was obtained in 87% yield and 90% ee. The benzothiophene derivative **10** was obtained in 80% yield.

8-Aminoquinoline directing group can be used for diarylation of methyl and monoarylation of methylene functionalities (Scheme 3). Diarylation of **11** was accomplished by 3,4-dimethyl-1-iodobenzene and 4-iodobenzoic acid ethyl ester and the products **12** and **13** were isolated in excellent yields. Interestingly, arylation of methylene groups occurs with high diastereoselectivity favoring the anti diastereomers. Protected phenylalanine can be arylated by 4-iodoanisole to give 91% of the product **14** with crude diastereomer ratio 24:1. Similarly, arylation by 2-iodothiophene results in formation of a single diastereomer **15** in 95% yield. Protected lysine can be arylated by 4-iodoanisole and 2-iodothiophene in high yields and diastereoselectivities. Arylation of a leucine derivative affords products **18** and **19** in high yields. The reactions were typically run on a 0.5 mmol scale. A 5.55 mmol scale *p*-methoxyphenylation of the leucine derivative afforded **18** in 67% yield. Cleavage of directing group was investigated for **12** and **18**. Methyl esters **20** and **21** were obtained in 80 and 58% yields, respectively. Compound **21** was produced in 86% ee that could be upgraded to 95% ee (85% recovery) by one recrystallization. Additionally, relative stereochemistry of **21**, which is a derivative of highly constrained β -isopropyltyrosine,^[13] was verified by X-ray crystallography.

Preliminary results in alkylation and acetoxylation of amino acid C-H bonds are reported in Scheme 4. Thus, alanine derivative **11** was alkylated by 1-iodooctane affording **22** in 42% yield. Compound **22** is a derivative of a lipidic amino acid which has shown tumor cell growth inhibitor activity.^[14] Acetoxylation of **23** gave **24** in 53% yield.^[15–16]

The arylation diastereoselectivity is set either at the C-H activation or, less likely, at reductive elimination step.^[17] The H/D exchange in **23** was examined by heating the substrate with catalytic $\text{Pd}(\text{OAc})_2$ in $\text{CD}_3\text{CO}_2\text{D}$ -toluene- d_8 mixture. (Scheme 5). After 5

hours at 100 °C, 64% of deuterium incorporation was observed at 3S position with minimal (<10%) incorporation at 3R position. A generalized reaction mechanism can be proposed. Formation of a palladium amide **23a** is followed by the C-H activation that affords **23b**. The complex **23b** then can be protonated or deuterated leading to **25**. Since protonation likely occurs with retention of configuration,^[18] it can be assumed that **23b** has a trans arrangement of phthaloyl and phenyl groups and that the diastereoselectivity of the arylation is set at the stage of palladation. Oxidative addition to give a high-valent^[19] Pd intermediate **26** is followed by reductive elimination that proceeds with retention of configuration. Oxidative addition of aryl iodides to palladium(II) may be facilitated by the silver salts since they are known to complex aryl iodides.^[20] Ligand exchange affords **27** and regenerates **23a**.

In conclusion, we have shown that synthesis of a number of substituted phenylalanine derivatives is possible by using C-H bond functionalization methodology. The syntheses are highly convergent and employ *N*-phthaloylalanine possessing a 2-thiomethylaniline directing group. The use of 8-aminoquinoline directing group allows for the diarylation of methyl and diastereoselective monoarylation of amino acid methylene groups. Acetoxylation and alkylation of amino acid derivative C-H bonds is also possible.

Experimental Section

(S)-*N*-(3-(Benzothiophene-2-yl)-2-phthalimidopropionyl)-2-methylthioaniline (7)

To a 1-dram vial was added (S)-*N*-(2-phthalimidopropionyl)-2-methylthioaniline (170 mg, 0.5 mmol), Pd(OAc)₂ (6 mg, 0.027 mmol), 2-iodobenzothiophene (785 mg, 3.0 mmol), AgOAc (209 mg, 1.25 mmol), and toluene (0.4 mL). The mixture was stirred at 60 °C for 64 h. After cooling to room temperature, the reaction mixture was diluted with CH₂Cl₂ (25 mL) and extracted with brine (15 mL). The aqueous layer was extracted with CH₂Cl₂ (2×15 mL). Combined organic layers were dried over MgSO₄. Evaporation to remove the organic solvents followed by purification by flash chromatography in hexanes/EtOAc (100% hexanes to 3:1) and preparative HPLC in hexanes/EtOAc 4:1 gave 175 mg of colorless oil (74%). R_f = 0.45 (SiO₂, 1/2 EtOAc/hexanes). ¹H NMR (500 MHz, CDCl₃, ppm) δ 8.95 (s, 1H) 8.37-8.31 (m, 1H) 7.87-7.82 (m, 2H) 7.75-7.67 (m, 3H) 7.62-7.58 (m, 1H) 7.45-7.41 (m, 1H) 7.33-7.20 (m, 4H) 7.80-7.04 (m, 1H) 5.40 (dd, 1H, *J* = 5.7, 10.3 Hz) 4.03 (dd, 1H, *J* = 5.1, 14.9 Hz) 4.11 (dd, 1H, *J* = 10.9, 15.5 Hz) 2.13 (s, 3H). ¹³C NMR (125 MHz, CDCl₃, ppm) 167.8, 165.8, 140.1, 139.9, 138.0, 134.7, 133.6, 131.5, 129.4, 125.5, 125.0, 124.3, 124.1, 123.9, 123.4, 123.3, 122.3, 120.6, 55.9, 29.7, 19.2. Signal for one carbon could not be located. FT-IR (neat, cm⁻¹) 1715, 1513, 1436, 1380. Calcd for C₂₆H₂₀N₂O₃S₂ (472.58 g/mol) C: 66.08; H: 4.27; N: 5.93; Found C: 65.82; H: 4.45; N: 5.72.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the Welch Foundation (Grant No. E-1571), NIGMS (Grant No. R01GM077635), and Camille and Henry Dreyfus Foundation for supporting this research. We also thank Dr. James Korp for collecting and solving the X-ray structure of **21**.

References

- Reviews: Colby AD, Bergman RG, Ellman JA. Chem Rev. 2010; 110:624. [PubMed: 19438203]
Ackermann L, Vicente R, Kapdi AR. Angew Chem Int Ed. 2009; 48:9792. Angew Chem. 2009; 121:9976. Chen X, Engle KM, Wang DH, Yu JQ. Angew Chem Int Ed. 2009; 48:5094. Angew

- Chem. 2009; 121:5196. Seregin IV, Gevorgyan V. *Chem Soc Rev.* 2007; 36:1173. [PubMed: 17576484] Lyons TW, Sanford MS. *Chem Rev.* 2010; 110:1147. [PubMed: 20078038] Daugulis O, Do HQ, Shabashov D. *Acc Chem Res.* 2009; 42:1074. [PubMed: 19552413] Alberico D, Scott ME, Lautens M. *Chem Rev.* 2007; 107:174. [PubMed: 17212475] Messaoudi S, Brion JD, Alami M. *Eur J Org Chem.* 2010:6495. Yeung CS, Dong VM. *Chem Rev.* 2011; 111:1215. [PubMed: 21391561] Sun CL, Li BJ, Shi ZJ. *Chem Commun.* 2010:677. Li CJ. *Acc Chem Res.* 2009; 42:335. [PubMed: 19220064] Jazzar R, Hitce J, Renaudat A, Sofack-Kreutzer J, Baudoin O. *Chem-Eur J.* 2010; 16:2654. [PubMed: 20143359] Catellani M, Motti M, Della Ca' N, Ferraccioli R. *Eur J Org Chem.* 2007:4153.
2. a) O'Malley SJ, Tan KL, Watzke A, Bergman RG, Ellman JA. *J Am Chem Soc.* 2005; 127:13496. [PubMed: 16190703] b) Wang DH, Yu JQ. *J Am Chem Soc.* 2011; 133:5767. [PubMed: 21443224] c) Mandal D, Yamaguchi AD, Yamaguchi J, Itami K. *J Am Chem Soc.* 2011; 133:19660. [PubMed: 22074290] d) Marcé P, Díaz Y, Matheu I, Castellón S. *Org Lett.* 2008; 10:4735. [PubMed: 18816138] e) Larivée A, Mousseau JJ, Charette AB. *J Am Chem Soc.* 2008; 130:52. [PubMed: 18067305] f) Chaumontet M, Piccardi R, Baudoin O. *Angew Chem Int Ed.* 2009; 48:179. *Angew Chem.* 2009; 121:185. g) Dangel BD, Godula K, Sezen B, Sames D. *J Am Chem Soc.* 2002; 124:11856. [PubMed: 12358522] h) Ahrendt KA, Bergman RG, Ellman JA. *Org Lett.* 2003; 5:1301. [PubMed: 12688744] i) Bowie AL Jr, Hughes CC, Trauner D. *Org Lett.* 2005; 7:5207. [PubMed: 16268539] j) Leblanc M, Fagnou K. *Org Lett.* 2005; 7:2849. [PubMed: 15987152]
3. a) Dyker G. *Angew Chem Int Ed Engl.* 1994; 33:103. *Angew Chem.* 1994; 106:117. b) Barder TE, Walker SD, Martinelli JR, Buchwald SL. *J Am Chem Soc.* 2005; 127:4685. [PubMed: 15796535] c) Chaumontet M, Piccardi R, Audic N, Hitce J, Peglion JL, Clot E, Baudoin O. *J Am Chem Soc.* 2008; 130:15157. [PubMed: 18928284] d) Lafrance M, Gorelsky SI, Fagnou K. *J Am Chem Soc.* 2007; 129:14570. [PubMed: 17985911] e) Liégault B, Fagnou K. *Organometallics.* 2008; 27:484. f) Wang DH, Wasa M, Giri R, Yu JQ. *J Am Chem Soc.* 2008; 130:7190. [PubMed: 18479089] g) Chen X, Goodhue CE, Yu JQ. *J Am Chem Soc.* 2006; 128:12634. [PubMed: 17002342] h) Wasa M, Engle K, Yu JQ. *J Am Chem Soc.* 2009; 131:9886. [PubMed: 19580277] i) Yoo EJ, Wasa M, Yu JQ. *J Am Chem Soc.* 2010; 132:17378. j) Wasa M, Yu JQ. *Tetrahedron.* 2010; 66:4811. [PubMed: 20711414] k) Wasa M, Engle KM, Yu JQ. *J Am Chem Soc.* 2010; 132:3680. [PubMed: 20187642] l) Watanabe T, Oishi S, Fujii N, Ohno H. *Org Lett.* 2008; 10:1759. [PubMed: 18393521] m) Stowers KJ, Fortner KC, Sanford MS. *J Am Chem Soc.* 2011; 133:6541. [PubMed: 21476513] n) Deng G, Zhao L, Li CJ. *Angew Chem Int Ed.* 2008; 47:6278. *Angew Chem.* 2008; 120:6374. o) Hasegawa N, Charra V, Inoue S, Fukumoto Y, Chatani N. *J Am Chem Soc.* 2011; 133:8070. [PubMed: 21542614]
4. a) Zaitsev VG, Shabashov D, Daugulis O. *J Am Chem Soc.* 2005; 127:13154. [PubMed: 16173737] b) Shabashov D, Daugulis O. *J Am Chem Soc.* 2010; 132:3965. [PubMed: 20175511]
5. a) Reddy BVS, Reddy LR, Corey EJ. *Org Lett.* 2006; 8:3391. [PubMed: 16836413] b) Feng Y, Chen G. *Angew Chem Int Ed.* 2010; 49:958. *Angew Chem.* 2010; 122:970. c) He G, Chen G. *Angew Chem Int Ed.* 2011; 50:5192. *Angew Chem.* 2011; 123:5298. d) Gutekunst WR, Baran PS. *J Am Chem Soc.* 2011; 133:19076. [PubMed: 22066860]
6. a) Kast P. *ChemBioChem.* 2011; 12:2395. [PubMed: 21953917] b) Young TS, Schultz PG. *J Biol Chem.* 2010; 285:11039. [PubMed: 20147747] c) Nestor JJ Jr. *Curr Med Chem.* 2009; 16:4399. [PubMed: 19835565]
7. Sommer S, Weikart ND, Brockmeyer A, Janning P, Mootz HD. *Angew Chem Int Ed.* 2011; 50:9888. *Angew Chem.* 2011; 123:10062.
8. a) Ager, DJ. *Unnatural Amino Acids.* In: Gadamasetti, K.; Braish, T., editors. *Process Chemistry in the Pharmaceutical Industry.* Vol. 2. CRC Press; 2008. p. 157-179. b) Au-Yeung, TT-L.; Chan, S-S.; Chan, ASC. *Transition Metals for Organic Synthesis.* Beller, M.; Bolm, C., editors. Vol. 2. Wiley-VCH; 2004. p. 14-28. c) Perdih A, Dolenc MS. *Curr Org Chem.* 2011; 15:3750.
9. Wen S-J, Yao Z-J. *Org Lett.* 2004; 6:2721. [PubMed: 15281753]
10. Ma T, Gao Q, Chen Z, Wang L, Liu G. *Bioorg Med Chem Lett.* 2008; 18:1079. [PubMed: 18155519]
11. Miltsov S, Rivera L, Encinas C, Alonso J. *Tetrahedron Lett.* 2003; 44:2301.
12. Wildemann D, Erdmann F, Alvarez BH, Stoller G, Zhou XZ, Fanghänel J, Schutkowski M, Lu KP, Fischer G. *J Med Chem.* 2006; 49:2147. [PubMed: 16570909]

13. Lin J, Liao S, Han Y, Qiu W, Hrubby VJ. *Tetrahedron: Asymmetry*. 1997; 8:3213.
14. Wilke DV, Jimenez PC, Araujo RM, Barbosa da Silva WM, Pessoa ODL, Silveira ER, Pessoa C, Odorico de Moraes M, Skwarczynski M, Simerska P, Toth I, Costa-Lotufo LV. *Bioorg Med Chem*. 2010; 18:7997. [PubMed: 20943402]
15. Gou F-R, Wang X-C, Huo P-F, Bi H-P, Guan Z-H, Liang Y-M. *Org Lett*. 2009; 11:5726. [PubMed: 19924878]
16. a) Desai LV, Hull KL, Sanford MS. *J Am Chem Soc*. 2004; 126:9542. [PubMed: 15291549] b) Giri R, Liang J, Lei JG, Li JJ, Wang DH, Chen X, Naggar IC, Guo C, Foxman BM, Yu JQ. *Angew Chem Int Ed*. 2005; 44:7420. *Angew Chem*. 2005; 117:7586.
17. a) Stille, JK. *The Chemistry of the Metal-Carbon Bond*. Hartley, FR.; Patai, S., editors. Vol. 2. Wiley; New York: 1985. chap. 9b) Netherton MR, Fu GC. *Angew Chem Int Ed*. 2002; 41:3910.
18. a) Fryzuk MD, Bosnich B. *J Am Chem Soc*. 1979; 101:3043. b) Labinger JA, Hart DW, Seibert WE III, Schwartz J. *J Am Chem Soc*. 1975; 97:3851.
19. Intermediate 25 is drawn as a Pd^{IV} complex. However, intermediacy of Pd^{III} complexes cannot be excluded. Powers DC, Geibel MAL, Klein JEMN, Ritter T. *J Am Chem Soc*. 2009; 131:17050. [PubMed: 19899740] Deprez NR, Sanford MS. *J Am Chem Soc*. 2009; 131:11234. [PubMed: 19621899] Cauty AJ. *Acc Chem Res*. 1992; 25:83. Amatore C, Catellani M, Deledda S, Jutand A, Motti E. *Organometallics*. 2008; 27:4549.
20. Powell J, Horvath M, Lough A. *J Chem Soc, Chem Commun*. 1993:733.

Scheme 1.
Auxiliaries for C-H Bond Arylation

Scheme 2.
Synthesis of Modified Phenylalanine Derivatives.

Scheme 3.
Aminoquinoline Auxiliary.

Scheme 4.
Alkylation and Acetoxylation.

Scheme 5.
Mechanistic Considerations.

Table 1

Reaction Optimization.

Entry	Base	Temp, °C	% conv, 3	% ee, 4
1[a]	CsOAc	110	68	77
2[a-c]	CsOAc	90	61	55
3[a]	CsOAc	60	51	92
4[d]	AgOAc	70	90	88
5[b],[d]	AgOAc	60	78	92
6[d]	AgOCOCF ₃	70	78	91
7[d]	AgOCOCF ₃	60	77	92
8[d-e]	AgOCOCF ₃	70	59	93
9[b],[d],[f]	AgOCOCF ₃	110	82	67

[a] Toluene solvent.

[b] Isolated yield.

[c] Pivalic acid additive.

[d] No solvent.

[e] $\text{Pd}(\text{OCOCF}_3)_2$ catalyst.

[f] Reaction time 12 h. See supporting information for details.